天康生物(002100.SZ):2月生豬銷售收入環比降35.64% 同比增143.69%
格隆匯3月9日丨天康生物(002100.SZ)發佈2021年2月份生豬銷售簡報,2021年2月份銷售生豬10.05萬頭,銷量環比下降33.44%,同比增長193.86%;銷售收入2.51億元,銷售收入環比下降35.64%,同比增長143.69%。
2021年2月份商品豬(扣除仔豬、種豬後)銷售均價24.98元/公斤,均重145.39公斤。
2021年1-2月,公司累計銷售生豬25.15萬頭,較去年同期增長185.15%;累計銷售收入6.40億元,較去年同期增長135.29%。
2021年2月,公司生豬銷量、銷售收入環比下降的主要原因是2月正值春節假期,銷售天數較其他月份減少,又適逢春節市場消費淡季,公司生豬出欄量減少,以及生豬銷售均價環比下降所致。
2021年2月,公司生豬銷量、銷售收入同比增長的主要原因是是新疆、河南的新建養殖基地投產後,養殖規模擴大所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.